Study on Plasmablastic Lymphoma Patients
ConditionPlasmablastic Lymphoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15+
SponsorFondazione Italiana Linfomi - ETS
About this trial
This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022
Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report
Age > 18 years old
Availability of complete medical records
Disqualifiers
Any other histology than PBL
Lack of complete medical records
Lack of histopathological material requested by the study
Trial population
Patients (Age ≥ 18 years old) with diagnosis of plasmablastic lymphoma (Histologically confirmed) between Jan 1st 2000, and Dec 31st 2022
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
200 Participants
are grouped into 1 trial groupGroup A: Plasmablastic lymphoma patients
Trial outcomes
Primary outcomes
1
Overall Survival (OS)
OS is defined as the time from the diagnosis to death for any cause or last clinical contact for censored patients.
Time frame
36 monthsSecondary outcomes
1
ECOG-PS
Proportion of Performance Status: from 0 (fully active) to 4 (Completely disabled)
Time frame
36 months2
Ann Arbor Stage
Proportion of stage: from I (better) to IV (worse)
Time frame
36 months3
Kidney and/or adrenal gland involvement
Proportion of the presence of involvement
Time frame
36 months4
Diagnostic liquor
Proportion of the presence of liquor
Time frame
36 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Fondazione Italiana Linfomi - ETS
Lead sponsor
AIL Roma - Italia
Collaborator
AIL Cuneo - Italia
Collaborator
Source ClinicalTrials.gov